Can I Take St. John's Wort with Amlodipine?

Does St. John's Wort Interact with Amlodipine?

Yes, and the interaction is considered clinically significant. St. John's Wort activates pregnane X receptor (PXR), which drives transcription of CYP3A4 and P-glycoprotein in intestinal and hepatic tissue. Amlodipine is a high-extraction CYP3A4 substrate, so increased enzyme activity accelerates first-pass and systemic metabolism, dropping plasma drug levels. A reduction in area under the curve (AUC) of 30 to 70% has been documented for CYP3A4-dependent calcium channel blockers as a drug class [1, 2].

The Pharmacokinetic Mechanism

Amlodipine is almost entirely metabolized by CYP3A4 in the gut wall and liver [3]. St. John's Wort contains two active constituents, hyperforin and hypericin. Hyperforin is the dominant PXR ligand responsible for CYP3A4 induction [4]. Standard commercial preparations delivering 300 mg three times daily (a common labeled dose) contain roughly 3 to 5% hyperforin by weight, enough to produce measurable enzyme induction within 3 to 5 days of regular use [5].

What Happens to Amlodipine Blood Levels

When CYP3A4 activity rises, amlodipine is cleared faster. The half-life of amlodipine under normal conditions is 30 to 50 hours [3]. Accelerated clearance shortens the effective half-life and lowers steady-state trough concentrations. The clinical result is a drug that behaves as if the patient is receiving a meaningfully lower dose, even though the tablet dose has not changed.

A 2000 pharmacokinetic study by Johne et al. (N=8 healthy volunteers) showed that 14 days of St. John's Wort 300 mg three times daily reduced the AUC of the immunosuppressant cyclosporine (also a CYP3A4 substrate) by approximately 52% [6]. The same CYP3A4 pathway governs amlodipine's clearance, making the parallel clinically relevant.

The P-glycoprotein Contribution

St. John's Wort also induces intestinal P-glycoprotein (P-gp), an efflux transporter that pumps drug back into the gut lumen [4]. Amlodipine is a mild P-gp substrate. While the magnitude of the P-gp contribution is smaller than the CYP3A4 effect for amlodipine specifically, both mechanisms push drug levels in the same direction: lower [3].

How Serious Is This Interaction?

The interaction carries a "major" severity rating in standard clinical drug interaction databases [7]. Loss of amlodipine efficacy can manifest as a return of hypertension or angina symptoms within one to two weeks of starting St. John's Wort. For a patient whose blood pressure was previously controlled at, say, 118/76 mmHg, undetected enzyme induction may allow systolic pressure to drift back above 140 mmHg, a range associated with measurably higher stroke and myocardial infarction risk [8].

Cardiovascular Risk Context

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) states that "each increment of 20 mmHg in systolic BP or 10 mmHg in diastolic BP doubles the risk of cardiovascular disease" [8]. A drug-level reduction sufficient to raise systolic pressure by 15 to 25 mmHg is therefore not a trivial concern. It falls within the range that clinicians treat aggressively with dose titration.

Angina Risk Is Separate and Additive

For patients taking amlodipine for vasospastic (Prinzmetal) or chronic stable angina, reduced drug levels can allow coronary vasospasm or demand-supply mismatch to recur. Angina episodes carry their own short-term risk, including progression to acute coronary syndrome in a small but real proportion of patients [9].

Who Is Most at Risk?

Patients who face the greatest clinical exposure from this interaction share several features.

High-Cardiovascular-Risk Patients

Anyone with established coronary artery disease, prior myocardial infarction, peripheral arterial disease, or diabetes-associated hypertension has less physiologic reserve to absorb a reduction in anti-hypertensive efficacy. These patients are precisely the population for whom amlodipine is most frequently prescribed [3].

Patients Using High-Hyperforin Formulations

Hyperforin content varies substantially across commercial St. John's Wort products. Standardized extracts delivering 3 to 5% hyperforin (often labeled "WS 5570" or "LI 160") produce strong CYP3A4 induction [5]. Low-hyperforin preparations (<0.5% hyperforin) show attenuated induction in pharmacokinetic studies, though they are less commonly sold and less likely to be found on supplement store shelves [4].

Older Adults

CYP3A4 expression declines modestly with age, but the relative change produced by St. John's Wort induction remains proportionally similar [10]. Older adults also tend to have less blood pressure variability tolerance and more comorbidities, magnifying the downstream risk of even partial loss of drug effect.

Time Course: When Does the Interaction Start and Stop?

Onset of Induction

CYP3A4 induction is not instantaneous. Gene transcription through PXR must increase, new enzyme protein must be synthesized, and intestinal/hepatic enzyme pools must reach a new, higher steady state. This process takes approximately 3 to 5 days to begin and 10 to 14 days to reach maximal effect with regular St. John's Wort use [4, 5].

A patient who takes one or two doses of St. John's Wort is unlikely to experience significant blood pressure change. A patient who self-starts a four-week "mood support" course without telling their cardiologist is at real risk of uncontrolled hypertension by week two.

Offset After Stopping

When St. John's Wort is discontinued, CYP3A4 activity returns toward baseline over approximately 14 days as existing enzyme protein is degraded and not replaced at the induced rate [5]. During that two-week offset window, patients stopping St. John's Wort may see amlodipine levels rise back toward normal therapeutic range. In practice, this is rarely dangerous because amlodipine has a wide therapeutic window, but blood pressure should still be monitored during this period to detect any clinically meaningful shift.

What Do Clinical Guidelines Say?

The FDA's guidance on drug interaction studies recognizes St. John's Wort as a "strong clinical inducer" of CYP3A4 and specifically lists it as a perpetrator that can "significantly reduce plasma concentrations of sensitive CYP3A4 substrates" [11]. Amlodipine is classified as a CYP3A4-sensitive substrate in FDA's drug interaction guidance tables [11].

The European Medicines Agency (EMA) issued a public statement as early as 2000 warning that St. John's Wort "interacts with and reduces the blood levels of" a range of CYP3A4-dependent drugs, including calcium channel blockers, and explicitly recommending that patients on these drugs not use St. John's Wort concurrently [12].

The American Heart Association's 2017 guideline on high blood pressure (Whelton et al., published in Hypertension) advises clinicians to "review all medications and supplements at each visit" and specifically flags herbal CYP450 inducers as a reversible secondary cause of apparent treatment-resistant hypertension [13].

"Apparent treatment-resistant hypertension should prompt evaluation for nonadherence and interfering substances, including herbal supplements with CYP3A4-inducing activity," the 2017 ACC/AHA guideline states [13].

What Should You Do If You Are Already Taking Both?

Do not stop either drug abruptly without speaking to your prescriber first. Abrupt cessation of St. John's Wort is lower risk than abrupt cessation of amlodipine, but a measured approach is still advisable.

Step 1: Tell Your Prescriber Immediately

Your prescriber needs to know you have been combining these two agents. Bring the St. John's Wort bottle to the appointment so your clinician can verify the hyperforin content and estimate how long induction may have been occurring.

Step 2: Check Your Blood Pressure

If your home blood pressure log shows readings that have drifted upward over the past two to four weeks, this is consistent with reduced amlodipine efficacy from CYP3A4 induction. Document readings every morning and evening for the 48 to 72 hours before your appointment [13].

Step 3: Supervised Discontinuation of St. John's Wort

In most cases, the clinically preferred path is to stop St. John's Wort and allow amlodipine levels to normalize over 10 to 14 days. Blood pressure monitoring every 48 to 72 hours during this period is reasonable to confirm the drug level is recovering [7].

Step 4: Consider Evidence-Based Alternatives for Mood Support

If you were taking St. John's Wort for mild-to-moderate depression or anxiety, raise that with your prescriber. Prescription options including SSRIs (which have their own interaction profiles but do not induce CYP3A4) or referral for cognitive behavioral therapy are alternatives that do not carry the same pharmacokinetic risk [14].

A 2008 Cochrane review (Linde et al., 29 trials, N=5,489) found St. John's Wort superior to placebo for mild-to-moderate depression but noted that "the clinical relevance of drug interactions must limit its use in patients on interacting medications" [14].

Monitoring Parameters If Combination Cannot Be Avoided

Avoiding the combination is the standard recommendation. However, if a short course of St. John's Wort is considered unavoidable (for example, a patient who cannot tolerate prescribed alternatives and whose mood disorder poses its own health risk), monitoring should include:

• Home blood pressure twice daily, logged and shared with the prescriber
• A clinic visit within 10 to 14 days of starting St. John's Wort to assess BP trend
• Possible amlodipine dose adjustment (titration from 5 mg to 10 mg daily may partially compensate, but this is an off-label mitigation, not an endorsed strategy)
• Reassessment of whether the mood indication can be addressed by a non-interacting agent within 30 days

No randomized trial has specifically tested amlodipine plus St. John's Wort co-administration in hypertensive patients. The risk inference draws on the well-characterized CYP3A4 induction data and the pharmacokinetic class effect for calcium channel blockers [1, 2, 5, 6].

Drugs in the Same Class: A Broader Warning

Other dihydropyridine calcium channel blockers share the same CYP3A4-dependent metabolism and carry equivalent interaction risk with St. John's Wort. These include felodipine, nifedipine, nisoldipine, and nicardipine [1, 2]. A 1999 study by Dresser et al. (N=9) specifically documented a 54% reduction in felodipine AUC after 14 days of St. John's Wort 300 mg three times daily, confirming the magnitude of the class effect [2].

Non-dihydropyridine calcium channel blockers verapamil and diltiazem are also CYP3A4 substrates and carry the same risk [3].

Common Misconceptions

"Natural means safe with my medications"

This is one of the most persistent misconceptions in supplement use. St. John's Wort affects the metabolism of cyclosporine, warfarin, HIV antiretrovirals, oral contraceptives, digoxin, and multiple antidepressants, among others [4, 6]. The EMA warning from 2000 listed more than 20 drug classes [12]. Being plant-derived does not reduce pharmacokinetic activity.

"A small dose of St. John's Wort won't matter"

Dose-dependent induction data do show that lower hyperforin exposures produce less induction [5]. A single low-dose exposure is unlikely to cause measurable BP change. But most patients who purchase St. John's Wort use it at labeled doses (300 mg three times daily) for weeks to months, the duration where full induction occurs.

"I can just separate the doses by a few hours"

Dose separation does not help pharmacokinetic induction interactions. CYP3A4 induction is a change in enzyme protein expression, not a transient competition for the same binding site. The enzyme remains elevated whether or not amlodipine and St. John's Wort are taken at different times of day [7].